UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Blake Insomnia
Therapeutics Inc.
(Name of Issuer)
COMMON
STOCK, $0.0001 PER SHARE PAR VALUE
(Title of Class of Securities)
093152 106
(CUSIP Number)
Morten
Albrechtsen
Blake
Insomnia Therapeutics Inc.
244,
5th Avenue, Suite A-154
NewYork,
N.Y. 10001
(646) 453-4912
(Name,
Address and Telephone Number of Person Authorized to
Receive
Notices and Communications)
August
31, 2015
(Date
of Event Which Requires Filing of this Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.[ ]
*The
remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior
cover page.
The
information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section
18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however,
see
the Notes).
1.
|
Names of Reporting Persons:
|
Morten Albrechtsen
|
|
|
|
|
2.
|
Check
the Appropriate Box if a Member of a Group (
See
Instructions)
|
|
(a) [ ]
|
|
(b) [
]
|
|
|
3.
|
SEC Use Only:
|
|
|
4.
|
Source of Funds (See Instruction):
|
PF
|
|
|
5.
|
Check if Disclosure of Legal Proceedings
is Required Pursuant to Items 2(d) or 2(e):
[ ]
|
|
|
|
|
6.
|
Citizenship or Place of Organization:
|
Denmark
|
|
|
Number of Shares Beneficially by
Owned by Each Reporting Person With:
|
|
|
7.
|
Sole Voting Power:
|
3,000,000 SHARES
|
|
|
|
8.
|
Shared Voting Power:
|
N/A
|
|
|
|
9.
|
Sole Dispositive Power:
|
3,000,000 SHARES
|
|
|
|
10.
|
Shared Dispositive Power:
|
N/A
|
|
|
|
|
|
|
11.
|
Aggregate Amount Beneficially Owned
by Each Reporting Person:
3,000,000 SHARES
|
|
|
|
|
|
|
12.
|
Check if the Aggregate Amount in
Row (11) Excludes Certain Shares (
See
Instructions):
[ ]
|
|
|
|
|
|
|
13.
|
Percent of Class Represented by
Amount in Row (11):
9.49%
(1)
|
|
|
|
|
|
|
14.
|
Type of Reporting Person (
See
Instructions):
IN
|
|
|
|
|
|
|
|
(1)
|
Based
on a total of 31,597,572 shares of the Issuer’s common stock outstanding as of
June 12, 2017.
|
|
ITEM
1.
|
SECURITY
AND ISSUER.
|
This
Statement on Schedule 13D relates to the common stock, par value $0.0001 per share (the “Shares”), of Blake Insomnia
Therapeutics Inc., a Nevada Corporation (the "Issuer"), and is being filed by Morten Albrechtsen (the “Reporting
Person”). The Issuer's current principal executive offices are located at 244, 5th Avenue, Suite A-154 New York, N.Y. 10001.
|
ITEM
2.
|
IDENTITY
AND BACKGROUND
|
(a)
through (c) and (f). This Statement is being filed by Morten Albrechtsen (the “Reporting Person”). The business address
of the Reporting Person is 244, 5th Avenue, Suite A-154 New York, N.Y. 10001. The Reporting Person is currently not an employed
by but working ad clinical advisor to the Issuer. The Reporting Person is a citizen of Denmark.
(d)
and (e). During the previous ten (10) years, the Reporting Person (i) has not been convicted in any criminal proceeding (excluding
traffic violations or similar misdemeanors) and (ii) has not been party to a civil proceeding of any of a judicial or administrative
body of competent jurisdiction such that, as a result of such proceeding, was or is subject to a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activity subject to, federal or state securities laws or finding any
violation with respect to such laws.
|
ITEM
3.
|
SOURCE
AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
|
This
statement relates to Shares in the Issuer that the Reporting Person has the right to acquire in sixty days. These securities in
the Issuer are described as follows:
|
·
|
Common
Stock in the Issuer totaling 3,000,000.
|
On
August 31, 2015, the Reporting Person was issued 1,500,000 shares for his services as an advisor and 1,500,000 in exchange for
$5,000.
|
ITEM
4.
|
PURPOSE
OF TRANSACTION
|
The
purpose of this Schedule 13D is to report the Beneficial Ownership by the Reporting Person of 3,000,000 shares or 9.49% of the
Issuer’s issued and outstanding common stock as of June 12, 2017.
Except
as provided below, the Reporting Person does not have any current plans or proposals which would relate to or would result in:
(a)
the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;
(b)
any extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;
(c)
a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries;
(d)
any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number
or term of directors or to fill any existing vacancies on the board;
(e)
any material change in the present capitalization or dividend policy of the Issuer;
(f)
any other material change in the Issuer's business or corporate structure including, but not limited to, if the Issuer is a registered
closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required
by Section 13 of the Investment Company Act of 1940;
(g)
changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede acquisition of
control of the Issuer by any person;
(h)
causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to
be quoted in an inter-dealer quotation system of a registered national securities association;
(i)
a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the
Act; or
(j)
any action similar to any of those enumerated above.
|
ITEM
5.
|
INTEREST
IN SECURITIES OF THE ISSUER.
|
|
(a)
|
The
Reporting Person is currently the beneficial owner of 3,000,000 shares of Common Stock
of the Issuer, representing approximately 9.49% of the Issuer's common stock (based upon
31,597,572 outstanding shares of common stock as of June 12, 2017).
|
|
(b)
|
The
Reporting Person has sole voting and dispositive power over the Shares identified in
response to Item 5(a) above.
|
|
(c)
|
See
response by Reporting Person to Item 4, above.
|
|
ITEM
6.
|
CONTRACTS,
ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.
|
Other
than as described in this Schedule 13D, the Reporting Person has no contracts, arrangements, understandings or relationships with
any other person with respect to any securities of the Issuer.
|
ITEM
7.
|
MATERIAL
TO BE FILED AS EXHIBITS.
|
None
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: July
13, 2017
By:
/s/ Morten Albrechtsen
Morten
Albrechtsen